Maria Hjorth is proposed to join the board of Monsenso as chairman

Maria Hjorth is proposed to join the board of Monsenso as chairman

Monsenso today announces that the board of Directors proposes Maria Hjorth to be elected for the board at the General Assembly on April 14th, 2021.

Monsenso – a leading provider of digital health solutions for mental health – plans to further strengthen the board by nominating a new professional board member with strong qualifications and competencies to support the company’s growth journey: Maria Hjorth, CEO at VP Securities A/S

Maria Hjorth will replace Jukka Pertola, who – as previously announced – will withdraw from the board of directors in order to comply with good board governance practices by reducing his number of board positions.

The board and the management of Monsenso would like to thank Jukka Pertola for his efforts in supporting the management, the company in general and particularly the listing on Nasdaq First North in 2020.

The new board plans to constitute itself with Maria Hjorth as the Chairman and Jakob Bardram as the Vice Chairman following the ordinary Annual General Meeting on April 14, 2021, where Jukka Pertola is expected to resign as the Chairman.

The nomination of Maria Hjorth follows a change in the board in January, where Peter Høngaard Andensen and Jacob Hahn Michelsen were elected with the aim to strengthen the competences and diversity of the board.

Jukka Pertola commented: ”It is sad to pass on the chairmanship, but I have to do so to comply with demands related to good corporate governance. On the other hand, I am very pleased that with Maria Hjorth and the changes made in January, we have a competent and experienced board that is well positioned to help Monsenso reach the next level. Jacob Hahn Michelsen and Peter Høngaard Andersen brought extensive experience in pharma- and health-related software, medical applications, science and research, pharmaceuticals, neurology, innovation and funding. Maria Hjorth’s experiences from top management, financial businesses, investor relations and M&A is a great supplement to the rest of the board”.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

The EcoWeb project has recruited more than 1600 participants across four countries despite COVID-19

The EcoWeb project has recruited more than 1600 participants across four countries despite COVID-19

Since the EcoWeB project launched MyMoodCoach (an app powered by Monsenso) in November 2020 it has recruited more than 1600 young participants in Belgium, UK, Spain and Germany.

The EcoWeB research study, led by Professor Ed Watkins University of Exeter, seeks to understand what influences mood, how emotions change over time, and which emotional skills increase well-being among youth.

The participants are asked to use MyMoodCoach to monitor their emotions in daily life, while giving them access to “Tools” and “Challenges” to boost their mental health and wellbeing. ‘Tools’ provide the participants with strategies to help them if they feel sad, stressed, anxious or have a problem. ‘Challenges’ help them to learn new skills, develop a positive mindset, improve their confidence and gain insight into their emotions.

The strong pick up of MyMoodCoach reflects a desire among youth to take better care of their mental wellbeing.

“We are very pleased to contribute to this project, as young people have been particularly impacted by COVID-19.” says Thomas Lethenborg, CEO of Monsenso. “Mobile health solutions have proved true value during the pandemic, allowing both clinical practice and important research projects to continue despite lockdowns.”

About the project:

The EcoWeB project is led by Professor Ed Watkins, University of Exeter, and involves 13 different institutions across 8 European nations (the UK, Germany, Belgium, Spain, Greece, the Czech Republic, Denmark, and Switzerland). The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 754657.

About Monsenso digital health solution:
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

Monsenso expands in the Middle East with new million deal with global pharmaceutical company

Monsenso expands in the Middle East with new million deal with global pharmaceutical company

Monsenso has entered a new million agreement with a global pharmaceutical company and hereby expands its activities to six countries in the Middle East. As part of the agreement, Monsenso will provide its solution for patient monitoring and treatment support in the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar and Bahrain.

Monsenso’s solution will be used to support the treatment of depression and schizophrenia. Patients are provided with an app, which is used to collect real-time patient-reported information and to give patients access to information about their disorder between consultations. Therapists gain access to a clinical web portal and can follow their patients remotely and gain valuable information about behavior, medication intake and symptoms and thus be able to provide a data-driven treatment and allow for proactive follow-up.
In addition, the solution supports communication between patients and therapists.

“We are very pleased with this agreement, which contributes to both expanding our geographic market coverage and our business with pharmaceutical companies in line with our growth strategy. ” says Thomas Lethenborg, CEO of Monsenso. “Depression and schizophrenia are among the most costly disorders for society and have major consequences for affected patients and relatives. Therefore, we are proud to be able to contribute to better treatment within these disease areas.”

The project will not affect Monsenso’s previously communicated plans and guidance for the 2020 financial year.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Harnessing mHealth with addiction at Amy’s Place

Harnessing mHealth with addiction at Amy’s Place

This is the reposting of an original article written by Centra Group. You can read the original article here.

Monsenso is proud to announce a new working partnership with UK’s telecare provider, Centra. The joint work will explore new, digital approaches to mental health service provision at Amy’s Place’ – Centra’s and Amy Winehouse Foundation’s (AWF) flagship addiction recovery service in East London.

The Monsenso mHealth app offers a comprehensive solution for managing a range of affective disorders, including depression, bipolar disorder, schizophrenia and borderline personality disorder. By utilising everyday smartphone technology, Monsenso supports individuals to self-manage their conditions whilst providing valuable insights to their mental health or social care support worker.

The Monsenso solution combines self-reported data and environmental sensor data to provide a balanced view of an individual’s behaviour and mood over time. The data can be accessed by nominated support staff to help inform diagnosis and treatment pathways.

Over the past ten months Centra’s Research and Innovation (R&I) team has worked closely with Monsenso as well as staff and residents at Amy’s Place to evaluate and configure the solution.

A pilot program will be established for six months, with testing conducted by a group of young women currently living at Amy’s Place and their support workers. Throughout the pilot, the service will be evaluated and supported by Centra’s R&I team to ensure that it meets expectations and maximises its benefits..

About Centra
Centra is one of UK’s largest providers of telecare services delivering a range of life-saving alarm and monitoring services to social care workers, housing associations, health professionals, local authorities and individuals. Supporting over 100,000 customers across the country, our aim is to help people live safely and independently for longer. Our in-house Telecare team provide 24/7 call monitoring and support our clients with wellbeing checks, automated “I’m OK” calls and scheduled medication reminders. We also offer GPS-enabled devices for round-the-clock support away from home. As industry leaders, we provide cutting-edge technology solutions and tailored support that help meet customers’ ever-changing needs. To learn more, visit www.centragroup.org.uk

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit www.monsenso.com.

About the Amy Winehouse Foundation
The Amy Winehouse Foundation works to prevent the effects of drug and alcohol misuse on young people. We also aim to support, inform and inspire vulnerable and disadvantaged young people to help them reach their full potential. We are driven by a powerful vision for young people, a world where young people can flourish. To learn more, visit www.amywinehousefoundation.org

Using mobile technology to reduce hospital re-admissions

Using mobile technology to reduce hospital re-admissions

The U.S Healthcare Information and Management Systems Society (HiMSS) released a report titled “Leveraging mobile technology to reduce hospital readmissions.”

According to the Centres for Medicare and Medicaid Services (CMS), Medicare has been overwhelmed with excessive hospital re-admissions – with total costs up to $17.5 billion a year. [1]

From 2007 to 2010, the national re-admissions rate remained at 19.2%, with an average Medicare cost for a hospital readmission stay at $9,600.

Therefore, the Hospital Re-admissions Reduction Program (HRRP), under the Affordable Care Act (ACA), aims to reduce re-admissions for all acute-care hospitals receiving payment under the Medicare Inpatient Prospective Payment System. [1]

In 2012, more than 2,000 hospitals were penalized for having excessive re-admission rates. The Medicare Payment Advisory Committee (MedPAC) estimates that these hospitals paid an average penalty of $125,000. [1]


Mobile technology ripe for greater adoption

Hospitals and health care systems are looking into developing new strategies, redesigning discharge procedures, and hiring more staff to follow up with patients at home.

They also need to rely on health information technology to scale their programs since they are also required to meet meaningful use criteria.

Hospitals and health systems are being urged to include mobile technology such as remote monitoring devices to connect patients and clinicians and impact care outside of their organizations.

According to the Pew Mobile technology fact sheet, as of October 2014, 64% of American adults have a smartphone. [2]

According to the 2015 HIMSS Mobile Technology Survey, 90% of respondents uses at least one type of mobile device to engage patients. [3]

Mobile health technology has created a demand for the concept of care from any location, which includes being able to communicate, share patient information, and receive services remotely.

The acceptance of mobile technology in the care setting continues to grow. 52% of survey respondents believe that the use of mobile technology will “substantially impact the delivery of healthcare in the future.” An additional 16% noted that the use of mobile technology will “dramatically change the way healthcare is delivered in the future.” [1]

Respondents also ranked that medication reminders, remote patient monitoring and preventative support care are benefits that mobile technology can deliver on patient care.


Overcoming the barriers

While remote monitoring technology (RMT) and mobile technology improve the quality of care and outcomes overall, barriers still exist.

In the case of mental health, mobile technology solutions like the one offered by Monsenso can help reduce the number of hospital re-admissions as well as the health care spending.

For example, a patient is brought into the emergency room as a consequence of displaying severe symptoms of mental illness.

After a couple of weeks of hospitalisation, the patient is released into the care of a close relative. Even though things seem to be going well, the patient is readmitted to the hospital again after six months.

This scenario can be quite common for people suffering from severe mental illness. Patients receive the treatment they need while being hospitalised, however once they are released into the care of their relatives, they receive no support, which gradually deteriorates their mental health.

It is very seldom that patients suffering from mental illness are called in for follow-up appointments, and as a consequence patients remain “stable” for a short period and then hospitalised after relapses.

Monsenso mobile health solution

The Monsenso mHealth solution can help reduce the number of hospital re-admissions in psychiatric treatment. Once a patient is released from the hospital, clinicians can establish a remote care plan that includes monitoring and self-treatment.

Every day, patients will complete a self-assessment in their smartphone. The information on the self-assessment is synchronized in real-time with the clinical web portal.

With the information obtained from the self-assessments, the system can identify the triggers and early warning signs of all active patients. A clinician can access the system every morning and be informed on which patients may need urgent care.

After accessing the patient’s records and reviewing the patient’s behavioural patterns, the clinician can make an informed decision. He can determine if the patient needs to be called in for an emergency appointment or just monitored more closely.

The clinician can also send an encrypted message to the patient asking if everything is fine and encouraging the patient to reach out if he feels ill.

In addition, the Monsenso mHealth solution provides patients with personalised action plans that suggest certain activities in case the patient displays certain symptoms.

Sources:

[1] Leveraging mobile technology to reduce hospital readmissions. Healthcare Information and Management Systems Society (HiMSS). 2013 http://www.mhealthnews.com/resource/leveraging-mobile-technology-reduce-hospital-readmissions

[2] Mobile technology fact sheet. Pew Research Center. 2014 http://www.pewinternet.org/fact-sheets/mobile-technology-fact-sheet/

[3] Mobile technology survey. Healthcare Information and Management Systems Society (HiMSS). 2015 http://www.himss.org/ResourceLibrary/genResourceDetailPDF.aspx?ItemNumber=42595